Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OCV C01

Next Previous
Drug Profile

OCV C01

Alternative Names: C01; OCV-C01

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTherapy Science; Otsuka Pharmaceutical
  • Developer OncoTherapy Science
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 23 Dec 2013 Discontinued - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)
  • 29 Jul 2013 Phase-III development for Pancreatic Cancer (second-line therapy or greater) is ongoing in Japan (SC)
  • 02 Nov 2012 Suspended - Phase-III for Pancreatic cancer (second-line therapy or greater) in Japan (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top